Glucosamine and Chondroitin Effects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A common starting dose of glucosamine and chondroitin will reduce inflammation as reflected by a reduction in serum C-reactive protein.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Absorption and Distribution of Glucosamine and Chondroitin

NCT00086229

Osteoarthritis

COMPLETED NA

N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)

NCT04706416

Coronavirus Covid19

COMPLETED PHASE1

Glucosamine Sulphate and Increased Level of Blood Cholesterol

NCT00251069

Osteoarthritis

COMPLETED PHASE4

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

NCT01550432

Obesity Hyperlipidemia Insulin Resistance +1 more

COMPLETED NA

Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19

NCT04703036

Covid19

TERMINATED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Use of glucosamine and chondroitin have been associated with reduced cancer and overall mortality. The aim of this study is to determine whether a common starting dose of glucosamine and chondroitin (1500 mg/d + 1200 mg/d, respectively) reduces systemic inflammation as reflected by a reduction in high sensitivity C-reactive protein.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glucosamine and Chondroitin

Group Type EXPERIMENTAL

Glucosamine and Chondroitin

Intervention Type DIETARY_SUPPLEMENT

Glucosamine (1500 mg) and Chondroitin (1200 mg)

Placebo

Inactive ingredients

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glucosamine and Chondroitin

Glucosamine (1500 mg) and Chondroitin (1200 mg)

Intervention Type DIETARY_SUPPLEMENT

placebo

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nutramax

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy
* Overweight (body mass index kg/m2 (BMI) between 25 and 32.5)
* Non-smoking men and women
* Aged 20-55y

Exclusion Criteria

* Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or inflammatory conditions (including autoimmune and inflammatory diseases)
* Pregnancy or lactation
* Currently on a weight-loss diet
* BMI (body mass index) \< 25 or \> 30
* Alcohol intake of greater than 2 drinks/day
* Current use of prescription or over-the-counter medications, (Excluding oral contraceptives and hormone-secreting IUDs), including use of aspirin or NSAIDs more than 2 days per week
* Abnormal renal, liver or metabolic test
* Inability to swallow pills
* Known allergy to shellfish
* Not willing to take pills made from shellfish or animal sources
* Intention to relocate out of study area within next 4 months

Minimum Eligible Age

20 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes